<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03216070</url>
  </required_header>
  <id_info>
    <org_study_id>HE17 00004</org_study_id>
    <nct_id>NCT03216070</nct_id>
  </id_info>
  <brief_title>Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia</brief_title>
  <official_title>Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce
      molecular response as first line therapy in CML.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will give 50mg of dasatinib daily since the diagnosis for up to 6 months, for the first
      2-4 weeks we will evaluate hematic biometry to registry hematic response, at months 3 and 6 a
      BCR/ABL PCR will be taken to evaluate molecular response.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2016</start_date>
  <completion_date type="Anticipated">October 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Molecular Response at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>Molecular Response define as BCR/ABL &lt;1%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early Molecular Response at 3 and 6 months</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Early Molecular Response define as &lt;10%</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Chronic Myelogenous Leukemia</condition>
  <arm_group>
    <arm_group_label>Arm1 Low Dose Dasatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We will give 50mg of dasatinib orally daily for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dasatinib 50 MG</intervention_name>
    <description>50mg of dasatinib orally daily</description>
    <arm_group_label>Arm1 Low Dose Dasatinib</arm_group_label>
    <other_name>Sprycel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of BCR-ABL positive CML in early chronic phase CML. Except for hydroxyurea,
             patients must have received no or minimal prior therapy, defined as &lt;2 weeks (14 days)
             of prior FDA approved TKI.

          -  ECOG performance of 0-2

          -  Adequate end organ function, defined as the following: total bilirubin &lt;1.5x ULN, SGPT
             &lt;2.5x ULN, creatinine &lt;1.5x ULN.

          -  Patients must sign an informed consent indicating they are aware of the
             investigational nature of this study.

        Exclusion Criteria:

          -  NYHA cardiac class 3-4 heart disease or previous pleural effusion.

          -  Pregnancy and lactation

          -  Patients with active, uncontrolled psychiatric disorders
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>David Gomez, MD</last_name>
    <phone>52 81 8348-8510</phone>
    <email>dr_gomez@infosel.net.mx</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopsital Universitario Dr. Jose E. Gonzalez, Centro Universitario contra el Cancer</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Gomez-Almaguer, MD</last_name>
      <phone>+52 81 8348-8510</phone>
      <email>dr_gomez@infosel.net.mx</email>
    </contact>
    <contact_backup>
      <last_name>Paola Santana, MD</last_name>
      <phone>+52 664 3864975</phone>
      <email>paola_santana72@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Gomez-Almaguer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Manuel Solano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Keskin D, Sadri S, Eskazan AE. Dasatinib for the treatment of chronic myeloid leukemia: patient selection and special considerations. Drug Des Devel Ther. 2016 Oct 13;10:3355-3361. eCollection 2016. Review.</citation>
    <PMID>27784993</PMID>
  </reference>
  <reference>
    <citation>Stein B, Smith BD. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. Clin Ther. 2010 May;32(5):804-20. doi: 10.1016/j.clinthera.2010.05.003. Review.</citation>
    <PMID>20685492</PMID>
  </reference>
  <reference>
    <citation>Tokarski JS, Newitt JA, Chang CY, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FY, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006 Jun 1;66(11):5790-7.</citation>
    <PMID>16740718</PMID>
  </reference>
  <reference>
    <citation>Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boqué C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2260-70. doi: 10.1056/NEJMoa1002315. Epub 2010 Jun 5.</citation>
    <PMID>20525995</PMID>
  </reference>
  <reference>
    <citation>Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, Hughes T, Bleickardt E, Strauss L, Francis S, Hochhaus A. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008 Jul 1;26(19):3204-12. doi: 10.1200/JCO.2007.14.9260. Epub 2008 Jun 9.</citation>
    <PMID>18541900</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>Dra. Olga Graciela Cantu Rodriguez</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Dasatinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dasatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

